Arrowhead Pharmaceuticals, Inc. (ARWR) Financials
ARWR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 626.3 million | 452.6 million |
2023-09-30 | 765.6 million | 478.4 million |
2023-06-30 | 795.9 million | 413.9 million |
2023-03-31 | 891.3 million | 426.2 million |
ARWR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -186.5 million | 19.7 million |
2023-09-30 | -89.2 million | 18.2 million |
2023-06-30 | -68.1 million | 19.9 million |
2023-03-31 | -59.0 million | 20.6 million |
ARWR Net Income
No data available :(
ARWR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 220.3 million | - | 118.6 million |
2023-09-30 | 403.6 million | - | 115.2 million |
2023-06-30 | 451.7 million | - | 82.7 million |
2023-03-31 | 481.0 million | - | 82.8 million |
ARWR Shares Outstanding
ARWR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 68.7 million | 116.5 million | 23.2 million | - |
2023-09-30 | 63.9 million | 99.9 million | 24.2 million | - |
2023-06-30 | 46.6 million | 94.8 million | 23.4 million | - |
2023-03-31 | 27.3 million | 74.9 million | 22.8 million | - |
ARWR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 3.6 million | 4.3 million |
2023-09-30 | 16.1 million | 3.9 million |
2023-06-30 | 15.8 million | 3.3 million |
2023-03-31 | 146.3 million | 2.7 million |
ARWR
Price: $22.12
52 week price:
Payout Ratio Range:
Earnings Per Share: -2.77 USD
P/E Ratio: -16.48
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 594870
Ebitda: -12.7 millionMarket Capitalization: 3.2 billion